Pharming Group
PHAR
Pharming Group (PHAR) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- $0.02
- EPS estimate
- $0.06
- EPS surprise
- −68.25%
- Revenue surprise
- −9.36%
- Revenue
- $90.2M
- Revenue estimate
- $99.5M
- Reported
- Jul 30, 2026
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Jul 30, 2026 | $0.06 | $0.02 | −68.25% | $90.2M | SEC |
| Q1 2026 | May 7, 2026 | $0.00 | −$0.07 | −7100.00% | $72.4M | SEC |
| Q4 2025 | Mar 12, 2026 | $0.02 | $0.07 | +366.67% | $106.5M | SEC |
| Q3 2025 | Nov 6, 2025 | $0.00 | $0.10 | +2122.22% | $97.3M | SEC |
| Q2 2025 | Jul 31, 2025 | −$0.11 | $0.06 | +157.14% | $93.2M | SEC |
| Q1 2025 | May 8, 2025 | −$0.03 | −$0.22 | −780.00% | $79.1M | SEC |
| Q4 2024 | Mar 13, 2025 | $0.02 | $0.05 | +163.16% | $92.7M | SEC |
| Q3 2024 | Oct 24, 2024 | −$0.00 | −$0.02 | −700.00% | $74.8M | SEC |
| Q2 2024 | Aug 1, 2024 | −$0.00 | −$0.02 | −900.00% | $74.1M | SEC |
| Q1 2024 | May 8, 2024 | $0.01 | −$0.19 | −2814.29% | $55.6M | SEC |
| Q4 2023 | Mar 14, 2024 | $0.00 | −$0.04 | −988.89% | $81.2M | SEC |
| Q3 2023 | Oct 26, 2023 | −$0.13 | $0.01 | +103.85% | $66.7M | SEC |
| Q2 2023 | Aug 3, 2023 | −$0.10 | $0.01 | +110.34% | $54.9M | SEC |
| Q1 2023 | May 11, 2023 | −$0.07 | −$0.17 | −161.54% | $42.5M | SEC |
| Q4 2022 | Mar 16, 2023 | $0.06 | −$0.21 | −472.73% | $54.6M | SEC |
| Q2 2022 | Aug 4, 2022 | $0.09 | $0.22 | +138.89% | $50.2M | — |
| Q1 2022 | May 12, 2022 | −$0.06 | $0.05 | +183.33% | $46.6M | — |
| Q4 2021 | Mar 17, 2022 | $0.00 | $0.02 | +328.57% | $52.8M | — |
Quarterly revenue
Frequently asked questions
When did Pharming Group (PHAR) last report earnings?
Pharming Group last reported on Jul 30, 2026, covering fiscal Q2 2026.
Did PHAR beat earnings estimates?
No. Pharming Group reported EPS of $0.02 for Q2 2026 against a $0.06 estimate — a 68.25% miss.
How much revenue did PHAR report last quarter?
Pharming Group reported $90.2M in revenue for Q2 2026, against a consensus estimate of $99.5M.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.